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Abstract
Purpose: The purpose of our study is to retrospectively review our institutional experience with adult rhabdomyosarcoma
(RMS) to determine presentation, prognostic factors and patterns of failure in this disease.
Materials and Methods: All patients  16 years with a diagnosis of rhabdomyosarcoma were retrospectively reviewed. Tumors
were classified according to the Intergroup Rhabdomyosarcoma Study (IRS) staging and grouping system. Median follow-
up for surviving patients was 12.5 years.
Results: A total of 39 patients (23 male, 16 female) were seen at our institution from 1961 to 1999. Median age was 45 years,
and age distribution showed a bimodal peak at the late teens to twenties and later in the sixties. Tumor in the extremity was
most common as seen in 15 (39%); this was followed by head and neck in 11 (28%), genitourinary in eight (20%), trunk/
retroperitoneum in four (10%) and other in one (3%). Tumor stage was T1 in 21 (52%) while 26 (67%) were >5cm in size.
Pleomorphic histology was most common (36%) and increased in incidence according to age category: 0% for ages 16–19,
27% for ages 20–49 and 60% for ages  50 years old (P<0.01). The median survival for the entire population was 2.25 years
with a 5-year overall survival rate of 35%. Multivariate analysis identified early IRS stage (P<0.001), non-embryonal
histology (P<0.009), favorablesite( P¼0.024), female gender (P¼0.034), early T-stage (P¼0.034) and absence of nodal
metastases (P¼0.037) as predictors of a better survival. The 5-year progression-free survival rate was 21%. Female gender
(P¼0.002), non-embryonal histology (P¼0.009), early IRS stage (P¼0.02) and early T stage (P¼0.033) were found on
multivariate analysis to predict for improved progression-free survival. The 5-year local control rate was 51%, and
multivariate analysis found that only early T-stage was predictive of better local control (P¼0.045). Fiveof six Group II
patients and five of eight Group III patients who received radiotherapy (RT) were locally controlled. Only one of five Group
III patients was locally controlled without RT.
Conclusions: The overall prognosis of adult RMS is worse than reported in children, but age criteria within the adult
population did not further classify outcome. RT is an effective local modality providing local control in almost all Group II
and majority of Group III patients.
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Introduction
Rhabdomyosarcoma (RMS) is themost common
soft tissuesarcoma in thepe diatric population.
The median age at diagnosis is 5 years, and the
majority of reported cases are in children. As a result
of the cooperative efforts of the Intergroup
Rhabdomyosarcoma Study (IRS) Committee, chil-
dren now have expected 3-year overall and failure-
free survival rates of 86 and 77%.
1 TheIRS trials
have identified effective chemotherapy regimens and
have more clearly delineated the roles of surgery and
radiotherapy (RT).
Adults areuncommonly afflicte d with RMS. In a
study from Memorial Sloan-Kettering Cancer
Center, RMS comprised 2% of all soft tissue
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2 As a result,
there is paucity of information regarding the behavior
of this disease in this population. Few studies exist,
with limited numbers of patients. The purpose of our
study is to review our institutional experience with
adult rhabdomyosarcoma in an effort to better define
the presentation, prognostic factors and patterns of
failure.
Materials and methods
After obtaining internal review board approval, all
patients with a diagnosis of rhabdomyosarcoma were
identified in the tumor registry during the period
1961–1999. All availableme dical and radiothe rapy
records were reviewed. From this original cohort of
patients, the study population  16 years of age at
diagnosis was identified. Although the IRS included
patients 16–21 years, we chose to study cases  16
years because most of the available literature in
adults haveinclude d this agegroup. Pathologists at
our institution reviewed all biopsies and surgical
specimens. Immunohistochemical stains for desmin
and muscle-specific actin were positive for all
patients. In the latter part of the study, electron
microscopy and/or anti-Myo D1 stains were also
performed to further confirm the diagnosis of
rhabdomyosarcoma. Based on the above tests, two
patients originally thought to be malignant fibrous
histiocytoma were reclassified as pleomorphic RMS.
Cytogenetic studies were performed only in the last 9
years; abnormalities such as reciprocal translocations
between chromosomes 2 and 13 or between 1 and 13
verified the diagnosis of alveolar rhabdomyosarcoma.
In fivepatie nts, theRMS subtypecould not be
assessed as these cases were from the earlier part of
the study, and materials for pathological review were
not availableduring thetimeof this analysis.
Tumors were retrospectively classified according
to the IRS pretreatment staging and grouping system
and presented in Tables 1 and 2.
1 Thefollowing
variables were extracted from the existing records:
gender, age, T stage, N stage, M stage, size, location,
histology and type of treatment. Tumors were
classified according to sites found to carry prognostic
significancein childhood: favorable(orbit, parate stic-
ular, non-parameningeal head and neck) or unfavor-
able (extremity, bladder, prostate, parameningeal
sites, retroperitoneum, trunk, other). Non-embryo-
nal histology included those with pleomorphic,
alveolar, mixed alveolar–pleomorphic, botryoides
and NOS categories. Although sarcoma botryoides
is a subtype of embryonal histology, we analyzed the
classic embryonal histology as an entity because of
the better prognosis of the botryoides variety in
children. Thus for the rest of this study, embryonal
refers to the classic embryonal histology and does not
include the botryoides subtype. Surgery, RT and
chemotherapy (CT) were employed alone or in
varying combinations. The study endpoints were
overall survival, progression-free survival and local
control and were estimated using the Kaplan–Meier
method.
3 Cox proportional hazards regression
models were used to identify factors associated with
time until the event of interest.
4 Thebackward
stepwise model building technique was the multi-
variate analysis approach used to identify factors
associated with time to event of interest. Statistical
tests were performed using the SAS system.
5 The
median follow-up for all patients and for surviving
patients was 5.7 and 12.5 years, respectively.
Table 1. Intergroup rhabdomyosarcoma pretreatment staging system
Stage Site Invasiveness Size Nodal status Metastasis
Stage1 Favorable T1 or T2 a or b N0 or N1 M0
Stage2 Unfavorable T1 or T2 a N0 M0
Stage3 Unfavorable T1 or T2 b N0 M0
UnfavorableT1 or T2 a or b N1 M0
Stage4 Favorableor
Unfavorable
T1 or T2 a or b N0 or N1 M1
Favorable sites: non-bladder/non-prostate genitourinary sites, orbit, non-parameningeal head and neck. Unfavorable sites: parameningeal
head and neck, extremity, trunk, retroperitoneum. Invasiveness: T1, confined to site/organ of origin; T2, extension beyond site/organ of
origin. Size: a,  5cm; b, >5cm.
Table 2. Intergroup rhabdomyosarcoma study surgical
grouping system
Group I Localized disease, completely resected
Group II Compromised or regional resection
A Grossly resected with microscopic
residual tumor
B Regional disease, completely resected,
with nodes involved and/or tumor
extension into an adjacent organ
C Regional disease with involved nodes,
grossly resected, but with evidence
of microscopic residual tumor
Group III incomplete resection or biopsy with
gross residual disease
Group IV Distant disease at diagnosis
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Incidence and host characteristics
A total of 39 patients (23 male, 16 female)  16 years
were identified which represented 30% of all 130
rhabdomyosarcoma cases seen at the University of
Iowa during this time period. The median age at
diagnosis was 45 years. The distribution of age at
diagnosis is presented in Figure 1. A bimodal peak
was seen in the late teens to twenties and fifties to
seventies. Age distribution in years was as follows:
16–19 (26%), 20–29 (18%), 30–39 (2%), 40–49
(8%), 50–59 (13%), 60–69 (21%), 70þ (13%).
Tumor characteristics
The primary site location was the extremities in 15
(39%), head and neck in 11 (28%), genitourinary
system in eight (20%), trunk/retroperitoneum in four
(10%) and other in one (3%). The anatomic sub-
types of tumor location are presented in Table 3. The
orbit as a head and neck site was only found in one
patient who was 17 years. The majority of tumors
(52%) was T1 and did not invadeothe r structure s.
Two-thirds were larger than 5cm. The histological
subtype was pleomorphic in 14 (36%), embryonal in
10 (26%), alveolar in eight (20%), mixed alveolar-
pleomorphic in one (3%), sarcoma botryoides in one
(3%) and not otherwise specified (NOS) in five
(13%). Thedistribution of histological type s accord-
ing of ageof patie nt is shown in Table4.
Pleomorphic histology was not found in any patients
16–19 years of age but was seen in 27 and 60% of
thoseage d 20–49 and  50 years, respectively
(P<0.001). On the other hand, embryonal histology
was seen in 80, 18 and 0% of patients aged 16–19,
20–49 and  50 years, respectively.
Regional nodal metastasis was noted in seven
(18%), while distant metastasis was seen in six
patients (15%). Of the seven who had regional nodal
metastases at initial diagnosis, primary site location
was the extremity in two, paratesticular region in
two, soft palate in one, prostate in one and mediasti-
num in one. For the six who initially presented with
distant metastasis, the sites of spread were pulmon-
ary in three, pulmonary and bone in one, bone
marrow in oneand live r in one . IRS Stagedistribu-
tion was as follows: Stage1 in five(12%), Stage2 in
11 (28%), Stage3 in 17 (44%) and Stage4 in six
(15%). Group classification was I in 14 (36%), II in
six (15%), III in 13 (33%) and IV in six (15%).
Treatment
Treatment varied over the study period. Twenty-
eight patients (72%) had an attempted resection;
subtotal resection with gross residual disease, total
Table 4. Number of patients according to age category and histology
Histology 16–19 years 20–49 years 50þ years Total (%)
Embryonal 8 2 0 10 (26)
Alveolar 2 3 3 8 (21)
Pleomorphic 0 3 11 14 (36)
Botryoides 0 0 1 1 (2)
Mixed Alveolar-pleomorphic 0 1 0 1 (2)
NOS 0 2 3 5 (13)
Total 10 (26) 11 (28) 18 (46) 39 (100)
NOS, not otherwise specified.
Table 3. Anatomic distribution of adult rhabdomyosarcoma
Location Frequency
Extremity 15 (38%)
Lower extremity 11
Upper extremity 4
Head and neck 11 (28%)
Paranasal sinuses 4
Nasopharynx 2
Pterygopalatine Fossa 1
Buccal mucosa 1
Soft Palate1
Neck 1
Orbit 1
Genitourinary 8 (21%)
Paratesticular 4
Bladder 2
Prostate2
Retroperitoneum 2 (5%)
Trunk 2 (5%)
Mediastinum 1 (3%) Fig.1. Distribution of rhabdomyosarcoma cases according to
age.
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resection with microscopic negative margins were
achieved in eight, six and 14 patients, respectively.
The other 11 patients (28%) had a biopsy only.
Chemotherapy was administered to 22 (56%) and
was more likely to be used after 1980. The most
commonly employed agents were vincristine (V),
actinomycin-D (A) and cyclophosphamide in seven,
actinomycin-D alonein four and VA in thre e
patients. Radiotherapy (RT) was given to 20
patients. RT was delivered to three Group I, six
Group II, eight Group III and three Group IV
patients. Treatment was to the primary site unless
there was pathologic nodal involvement; the draining
lymphatics were treated with nodal disease. Median
dosewas 5040cGy with a rangefrom 4000 to
6660cGy using 180–200-cGy fractions. Onepatie nt
with orbital RMS received 5550cGy using 110 cGy
given in a hyperfractionated fashion.
Overall and progression-free survival
Theme dian survival for thestudy population was
2.25 years. Five-year overall survival was 35%
(Figure2). On multivariateanalysis, e arly IRS stage
(P¼0.001), non-embryonal histology (P¼0.009),
favorablesite( P¼0.024), female gender
(P¼0.034), T1 stage( P¼0.034) and N0 stage
(P¼0.037) were predictive of an improved overall
survival. Use of chemotherapy did not affect survival
outcome. The patient and tumor characteristics
of the 10 patients with embryonal histology are
presented in Table 5. Univariate and multivariate
analysis for overall survival is presented in Table 6.
The 5-year progression free survival was 21%.
On multivariate analysis, female gender (P¼0.002),
non-embryonal histology (P¼0.004), T1 stage
(P¼0.033) and early IRS Stage (P¼0.02) were
all associated with an improved progression-free
survival.
Local control and patterns of failure
The5-ye ar local control ratewas 51%, and multi-
variateanalysis showe d that only T1 stage
(P¼0.045) was predictive for improved local con-
trol. Five of six (83%) of Group II patients receiving
RT were locally controlled. Among Group III
patients, five of eight (63%) receiving RT and one
of five (20%) not receiving RT were locally
controlled. One of the Group I patients failed in
theinguinal nodal re gion outsideof theRT fie ld,
which encompassed only the primary site in the
thigh. One of three Group I and two of three Group
IV patients were locally controlled with postoperative
and definitive RT, respectively. Local control
according to degree of surgical resection and use of
RT is presented in Table 7.
Fig.2. Overall survival for 39 adult rhabdomyosarcoma cases.
Table 5. Characteristics of patients with embry-
onal rhabdomyosarcoma
Agerange :
16–28 years
Gender (male:female) 8:2
Sites
Parameningeal site 5
Paratesticular site 3
Retroperitoneum 1
Orbit 1
IRS Group
I3
II 1
III 4
IV 2
IRS, Intergroup Rhabdomyosarcoma Study.
4 Simon et al.Nine patients did not have any recurrence. Of
the remaining 30 patients, nine (23%) had a
local recurrence alone, 14 (36%) had distant
metastasis alone and seven (18%) had both local
and distant metastases. Three of the seven who
had local and distant disease also had regional
nodal relapse. A total of 16 local failures (33%)
occurred at a median time of 4.5 months, all within
54 months from initial diagnosis. A total of 21 cases
(54%) had distant spread at a median time of 6
months. Of the three patients who failed at the
regional nodes, two had inguinal node recurrence
with a lower extremity primary site while another had
paraaortic node involvement and a paratesticular
tumor.
Discussion
Rhabdomyosarcoma is themost common soft tissue
sarcoma in children accounting for approximately
400 cases per year in the United States. The median
ageat diagnosis is 5 ye ars and ove r 80% of case s in
children occur before age 15. In the pediatric
population, thetumor most commonly arise s from
the head and neck (40%) followed by the genito-
urinarysites(20%)andextremities(20%).Embryonal
histology and sarcoma botryoides occur in 75% of
cases. Pleomorphic histology is almost always not
seen. The IRS studies have clearly defined prognos-
tic factors as well as effective chemotherapy agents
and RT regimens for this disease. Orbital, para-
testicular and non-parameningeal head and neck
sites have been found to be favorable location while
the parameningeal and extremity sites are considered
non-favorablesite s. Embryonal histology and sar-
coma botryoides have a better prognosis compared to
their alveolar counterpart. The success of the multi-
modality approach to thecurativetre atme nt of
childhood rhabdomyosarcoma is oneof thegre ate st
achievements in the past 35 years. The 3-year
survival of 85% in theIRS-IV is a re markable
testimony to the recent advances in the management
of this disease.
Adult rhabdomyosarcoma, on theothe r hand, is
less common and, as a result, less information is
availableto guideclinicians to thetre atme nt and
prognosis of the patient. In the most recently
reported IRS-IV, 17% of patients were  16 years
of age. In our study 30% of patients presenting with
rhabdomyosarcoma were aged 16 years or greater.
Two age peaks were found, one in early adulthood
and theothe r at lateadulthood. Although in childre n
treated in IRS-IV, age  10 years had a better 3-year
failure-free survival than those >10 years (83 vs.
68%, P¼0.001), our study showed that age in the
adult years did not further classify outcome.
In our study, the extremity was the most common
location followed by the head and neck region.
Orbital tumor was rare and was seen in only one
patient. Pleomorphic histology was the most
common subtype; this histological subtype was not
found in any of the patients aged 16–19, but was
found in 27 and 60% of thoseage d 20–49 and  50
years old, respectively. The Memorial experience
also demonstrated the preponderance of pleo-
morphic histology particularly in adults >40 years
Table 6. Univariate and multivariate analysis for overall survival
VariableUnivariate analysis Multivariate analysis
Agen.s. n.s.
Gender n.s. n.s.
Time era (pre-1980 vs. post-1980) n.s. n.s.
T-stagen.s. 0.034
N-stagen.s. 0.037
M-stage0.0046 n.s.
IRS stage0.0015 0.001
IRS group 0.0075 n.s.
Histology (E vs. non-E) n.s. 0.009
Site0.0618 0.024
Surgery n.s. n.s.
Radiotherapy n.s. n.s.
Chemotherapy n.s. n.s.
n.s., not significant at P¼0.05 level; E, embryonal histology.
Table 7. Local control according to degree of surgical resection and use of radiotherapy
Radiotherapy No radiotherapy Total
Group I 1/3 (33%) 8/11 (73%) 9/14 (64%)
Group II 5/6 (83%) – 5/6 (83%)
Group III 5/8 (63%) 1/5 (20%) 6/13 (46%)
Group IV 2/3 (67%) 1/3 (33%) 3/6 (50%)
Total 13/20 (65%) 10/19 (53%) 23/39 (59%)
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2 Some have questioned the existence of the
pleomorphic histology in adults, although recent data
confirm its status as a diagnostic entity.
6–8 More
commonly in the past, there has been some confu-
sion with thediagnosis of ple omorphic RMS and
malignant fibrous histiocytoma (MFH). In fact, two
of theple omorphic rhabdomyosarcomas in our study
were originally thought to be MFH, but further
immunohistochemical testing supported a RMS
diagnosis. Whereas in children, alveolar histology
has a worse survival compared to embryonal, our
review showed that adults with embryonal histology
had the worst survival. One should remember,
however, that we had small patient numbers and
that five patients treated in the earlier part of the
study had NOS histology and could not befurthe r
classified. Furthermore, of the 10 patients with
embryonal histology, two were Group IV and six
had a parameningeal or retroperitoneal tumor. The
finding of a worsesurvival in e mbryonal histology
should be interpreted with caution because of the
above reasons. In adults, embryonal histology has
not been found to have a better prognosis like in
children.
2,9
The survival of patients with RMS in our series
was only 35% at 5 and 10 years and is comparable to
the Memorial Sloan-Kettering and Harvard series.
Hawkins et al. reported the Memorial experience of
84 adult RMS patients and found a similar 5-year
survival of 35%.
2 Unlike our series, he found that
younger adult patients (aged 16–19) had a better
survival compared to those aged  20 years. Esnaola
et al. reviewed 39 adult RMS patients with a 5- and
10-year survival rate of 31 and 27%; age within the
adult years, like our study, did not predict for a better
outcome.
9
The survival rates, tumor and treatment charac-
teristics in different and present series are presented
in Table8.
2,9,10 The median age in our series is older
compared to the three other reported institutional
reviews and is consistent with a higher proportion of
pleomorphic RMS. Nodal metastases at initial
presentation were seen in 39 of the 178 (22%)
accumulated cases, which is in agreement with the
pediatric literature and the belief that RMS has a
relatively high incidence of lymph node metastasis.
Another observation is that almost all patients in the
Memorial, Harvard and Stanford reports have
received chemotherapy. Despite the consistent use
of systemic chemotherapy, the survival results were
dismal. We did not find the type of chemotherapy
agents used in our study to be beneficial in the
overall survival outcome. More effective chemother-
apy is needed in the treatment of adults with RMS
since 21 of 39 (54%) failed distantly. Because of the
high rate of distant metastasis, chemotherapy should
Table 8. Patient, tumor, treatment characteristics and survival rates in contemporary series of adult
rhabdomyosarcoma
Memorial (2)
n¼84
Harvard (6)
n¼39
Stanford (7)
n¼16
Iowa (present series)
n¼39
Median age (years) 23 26 25 45
Agerange(ye ars) 16–76 16–82 21–67 16–80
Histology
Embryonal (%) 51 18 56 26
Botryoides (%) 2 0 0 2
Pleomorphic (%) 17 13 0 36
Alveolar (%) 30 56 44 21
Mixed (%) 0 0 0 2
NOS (%) 0 13 0 13
Primary Site
Extremity (%) 22 31 12 39
Head and neck (%) 24 33 44 28
Genitourinary (%) 21 18 38 20
Other (%) 33 18 6 13
Tumor Size
 5cm (%) 36
a 38 na 33
>5cm (%) 43 62 na 67
% Nodal metastasis
b 84 64 4 1 8
% Distant metastasis
b 44 33 38 15
Treatment
Surgery (%) 75 54 38
c 72
Chemotherapy (%) 93 95 88 56
Radiotherapy (%) 49 69 100 51
Overall survival
5 years (%) 35 31 22 35
10 years (%) na 27 na 35
a, does not add to 100% because information is missing; b, at initial presentation; c, may be underestimated as
subtotal resections were not included; na, not available.
6 Simon et al.be strongly considered in the management of adult
RMS. In children with RMS, all receive chemother-
apy as part of their treatment course. We believe that
adult RMS has a worseprognosis compare d to
children based on our and previously cited institu-
tional reports. The extent of surgical resection was
not found to impact on overall survival or local
control in our study or the Harvard experience.
However, in the Memorial experience, patients with
negative margins of resection had a better disease-
specific survival compared to those with positive
margins of resection. Only tumor invasiveness
(T stage) was found on multivariate analysis to
predict for local control. The impact of RT on
improvement of local control is suggested by our
findings in Group II and III patients. Five of six
Group II and five of eight Group III patients were
controlled with RT while only one of five Group III
patients were controlled without RT. This finding
must be interpreted with caution given the small
number of cases. Because of the small patient
numbers it is unclear whether RT is important in
Group I or IV patients. RT may be useful in certain
subsets of patients with completely resected tumors.
In childhood RMS, an analysis of theIRS data
indicate an improvement in failure-free and overall
survival with theaddition of RT in Group I alve olar
histology.
11 For children with metastatic sarcoma,
the use of RT as consolidative treatment has been
found in a series from the University of Chicago to
improvelocal control.
12
Onecan concludethat local control is important in
thecurativetre atme nt of adult RMS. In the
Memorial experience, all local failures also experi-
enced distant failure either concurrently or after local
recurrence. In our experience, local recurrence was
accompanied or followed by distant failure in seven
of 16 cases (44%). Isolated nodal failure was not
found in any of our patients; all three who had lymph
node recurrence also had distant metastases at the
timeof failure , justifying our curre nt approach of not
prophylactically irradiating regional nodes without
pathological confirmation of cancer.
Our study is a retrospective analysis of adults with
RMS treated over a long period of time. It is also
important to notethat thepossibleprognostic factors
examined were those applicable to children based on
trials conducted by the IRS committee. We also had
fivepatie nts with a NOS classification and it was not
possible for all pathology to be reviewed using
modern diagnostic methods. Hence the prognostic
significanceof histology in our study should be
interpreted with caution. Despite these limitations,
our findings areimportant, as the reis paucity of
information regarding this particular soft tissue
sarcoma in adults. In conclusion, adult RMS carries
a much worseprognosis compare d to childhood
RMS. Our study, where a lower frequency of patients
received chemotherapy, showed the same poor
survival as theHarvard, Me morial and Stanford
studies, which almost always routinely employed
chemotherapy. We have also observed in adults that
tumors tend to occur in the unfavorable sites and,
like the Memorial series, have a higher proportion of
pleomorphic histology in the older patients.
Unfortunately, many patients develop metastatic
disease and the optimal chemotherapeutic regimen
remains to be defined in this unique population.
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